Enveric Biosciences (NASDAQ:ENVB) shares are trading higher after the company signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for pharmaceutical and non-pharmaceutical applications for joint diseases.
“We are pleased to announce that a second biotechnology company has stepped forward looking to join Enveric in moving some of the company’s promising assets forward,” said Joseph Tucker, Director and CEO of Enveric.
“Ultimately, we believe the definitive licensing agreements, once negotiated and finalized, could represent an excellent potential source of revenue for Enveric, and continue to demonstrate the value of ...